Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Teijin: Drug Sales, Profits to Plummet in FY2002
April 22, 2002
- WORLD NEWS IN BRIEF
April 22, 2002
- Hisamitsu: FY2001 Sales Up 6.6% to \69.5 Bil.
April 22, 2002
- Bayer Group to Increase Sales in Japan to \300 Bil. by 2004: Dr Portoff
April 22, 2002
- Pharmacia Starts Joint Research with Keio Univ.
April 22, 2002
- Pharmaceutical Industry Vision Drafted by Korosho
April 22, 2002
- Takeda Puts Brakes on High Hopes for TAK-165 Anticancer Agent
April 22, 2002
- 37 New Drugs Officially Approved
April 22, 2002
- Report on Future Trends in Regenerative Medicine Completed
April 22, 2002
- Korosho Presents Bill for Rivision of PAL to Diet
April 22, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
April 22, 2002
- 1,576 Firms Apply for Disclosure of PFSB Information
April 22, 2002
- Toshiba Forms Alliance with US Heartlab to Market Cardiovascular Information System
April 22, 2002
- Outline of Relief System for Victims of Tissue Engineering Products Recommended
April 15, 2002
- Terumo Latin America Established in Miami
April 15, 2002
- Plan of Reducing Subsidies to Public Corporations Approved
April 15, 2002
- Nabelin Fuji Science Ties Up with 2 Medical Devices Wholesalers
April 15, 2002
- REGULATORY NEWS IN BRIEF
April 15, 2002
- Oticon: New Hearing Aid Adapto
April 15, 2002
- BULLETIN
April 15, 2002
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…